Research ArticleGraft-Versus-Host Disease

Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF–licensed myeloid cells

See allHide authors and affiliations

Science Translational Medicine  28 Nov 2018:
Vol. 10, Issue 469, eaat8410
DOI: 10.1126/scitranslmed.aat8410

Keeping the baby but not the bathwater

The reconstituted immune system of an allogeneic hematopoietic cell transplant patient is responsible for preventing leukemia relapse by means of graft-versus-leukemia (GvL) activity. This same reconstituted immune system can turn on the recipient in the form of graft-versus-host disease (GvHD). Tugues et al. used multiple mouse transplant models to decipher the mechanisms driving GvHD and GvL. They discovered that GM-CSF–activated myeloid cells mediated GvHD, but did not contribute to GvL, which is largely carried out by T cells. These results suggest that blocking GM-CSF in hematopoietic cell transplant recipients may be able to specifically target cells that promote GvHD, without hampering those that enact GvL.

View Full Text

Stay Connected to
   Science Translational Medicine